Literature DB >> 17997706

Voltage-gated sodium channel blockers for the treatment of neuropathic pain.

Theodore R Cummins1, Anthony M Rush.   

Abstract

Pain serves a crucial physiological function, warning the body of impending or actual tissue damage, preventing further damage and aiding the healing process. Neuropathic pain, resulting from nervous system injury or dysfunction, can be a serious medical problem and especially difficult to treat. Although sodium channel blockers are clinically useful for treating pain, they often provide only partial relief and adverse effects associated with nonspecific actions can limit their use. Research on the roles of sodium channels in neuronal excitability and pain shows that specific sodium channel isoforms are crucial determinants of nociception and neuropathic pain, indicating that it should be possible to develop sodium channel blockers with lower toxicity and enhanced efficacy for treating neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17997706     DOI: 10.1586/14737175.7.11.1597

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  16 in total

1.  The tarantula toxins ProTx-II and huwentoxin-IV differentially interact with human Nav1.7 voltage sensors to inhibit channel activation and inactivation.

Authors:  Yucheng Xiao; Kenneth Blumenthal; James O Jackson; Songping Liang; Theodore R Cummins
Journal:  Mol Pharmacol       Date:  2010-09-20       Impact factor: 4.436

2.  Tarantula huwentoxin-IV inhibits neuronal sodium channels by binding to receptor site 4 and trapping the domain ii voltage sensor in the closed configuration.

Authors:  Yucheng Xiao; Jon-Paul Bingham; Weiguo Zhu; Edward Moczydlowski; Songping Liang; Theodore R Cummins
Journal:  J Biol Chem       Date:  2008-07-14       Impact factor: 5.157

Review 3.  Sodium channel blockers for the treatment of neuropathic pain.

Authors:  Anindya Bhattacharya; Alan D Wickenden; Sandra R Chaplan
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

Review 4.  The role of sodium channels in chronic pain.

Authors:  Simon R Levinson; Songjiang Luo; Michael A Henry
Journal:  Muscle Nerve       Date:  2012-08       Impact factor: 3.217

5.  Novel modulator of Na(V)1.1 and Na(V)1.2 Na channels in rat neuronal cells.

Authors:  Hua Mao; Lynne A Fieber; Robert E Gawley
Journal:  ACS Med Chem Lett       Date:  2010-03-31       Impact factor: 4.345

6.  Structural determinants of drugs acting on the Nav1.8 channel.

Authors:  Liam E Browne; Frank E Blaney; Shahnaz P Yusaf; Jeff J Clare; Dennis Wray
Journal:  J Biol Chem       Date:  2009-02-19       Impact factor: 5.157

7.  GpTx-1 and [Ala5 , Phe6 , Leu26 , Arg28 ]GpTx-1, two peptide NaV 1.7 inhibitors: analgesic and tolerance properties at the spinal level.

Authors:  Chao Chen; Biao Xu; Xuerui Shi; Mengna Zhang; Qinqin Zhang; Ting Zhang; Weidong Zhao; Run Zhang; Zilong Wang; Ning Li; Quan Fang
Journal:  Br J Pharmacol       Date:  2018-09-09       Impact factor: 8.739

8.  Regulation of the spontaneous augmentation of Na(V)1.9 in mouse dorsal root ganglion neurons: effect of PKA and PKC pathways.

Authors:  Jun-ichi Kakimura; Taixing Zheng; Noriko Uryu; Nobukuni Ogata
Journal:  Mar Drugs       Date:  2010-03-19       Impact factor: 5.118

Review 9.  The molecular basis of pain and its clinical implications in rheumatology.

Authors:  Brendan Bingham; Seena K Ajit; David R Blake; Tarek A Samad
Journal:  Nat Clin Pract Rheumatol       Date:  2009-01

10.  Structurally minimized mu-conotoxin analogues as sodium channel blockers: implications for designing conopeptide-based therapeutics.

Authors:  Tiffany S Han; Min-Min Zhang; Aleksandra Walewska; Pawel Gruszczynski; Charles R Robertson; Thomas E Cheatham; Doju Yoshikami; Baldomero M Olivera; Grzegorz Bulaj
Journal:  ChemMedChem       Date:  2009-03       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.